Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Refractory Non-Small Cell Lung Cancer
NCT00064350Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Jun 2004
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sorafenib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Number of Patients Maintaining Stable Disease or Objective Response 2 Months After Randomization. Started Jun 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00064350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00064350.